Latest Market Challenges News

Saluda Medical has obtained FDA approval for its CAP24 surgical paddle lead, a first-of-its-kind device designed for closed-loop spinal cord stimulation, poised to broaden its US market reach and engage new surgical specialties.

ArborGen Holdings reported a solid FY26 with record revenue driven by Brazil expansion and a 31% EBITDA increase, offsetting a challenging US market. Leadership changes and operational discipline mark the company’s path forward.

GTN Limited projects a sharp fall in FY26 earnings amid tough market conditions but signals a hefty dividend and a rebound in FY27 EBITDA.

Kingfish Limited posted a $13.6 million net loss for the year ended 31 March 2026, with portfolio returns lagging the benchmark amid geopolitical tensions and AI sector uncertainty.

AoFrio Limited has successfully closed a renounceable pro-rata rights issue, securing NZ$4.428 million to fund its push into US and European markets and advance AI-driven innovations in cold drink equipment.

Metcash Limited posted a modest rise in FY26 revenue and EBITDA, driven by strong Food segment growth and strategic acquisitions, while facing pressure in Hardware margins and suspending its Dividend Reinvestment Plan.

ECS Botanics has commenced commercial sales of Gelonoidz #20, its first Australian-grown Terphogz cultivar, marking a key step in expanding its premium medicinal cannabis portfolio with plans for more cultivars in FY27.

Ballymore Resources has secured $5.2 million through an oversubscribed capital raise, boosting its capacity to fast-track exploration across multiple Queensland projects.

Strata Investment Holdings has dismissed a cash acquisition proposal from Freedom BidCo, citing undervaluation, even as it raises A$8 million to fund strategic investments and litigation.

Bounty Oil & Gas NL has issued a prospectus offering over 632 million new options to eligible investors as part of a broader recapitalisation, potentially raising $6.3 million if exercised.

Akora Resources has pushed back the deadline for its $1.7 million entitlement offer to 19 June 2026, responding to shareholder feedback and ensuring broader participation.

Australian Clinical Labs appoints Greg Horan as Group CEO effective August 2026, marking a leadership transition after a decade under Melinda McGrath. Horan’s healthcare and operational expertise positions ACL for its next growth phase.